Synthesis and structure-activity relationship of a new series of potent angiotensin II receptor antagonists: Pyrazolo[1,5-α]pyrimidine derivatives

Chemical and Pharmaceutical Bulletin

Volumn 47, Issue 7, 1999, Pages 928-938

  Shiota, Takeshi ^a   Yamamori, Teruo ^a   Sakai, Katsunori ^a   Kiyokawa, Mitsugu ^a   Honma, Tsunetoshi ^a   Ogawa, Masayoshi ^a   Hayashi, Kunio ^a   Ishizuka, Natsuki ^a   Matsumura, Ken Ichi ^a   Hara, Mariko ^a   Fujimoto, Masafumi ^a   Kawabata, Tomoji ^a   Nakajima, Shigeyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Angiotensin II antagonist; Antihypertensive; Pyrazolo 1,5 pyrimidine

Indexed keywords

2 ETHYL 4 [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHOXY]QUINOLINE; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; 2 [N PROPYL N [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL]AMINO]NICOTINIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

EID: 0032783087     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.47.928     Document Type: Article

References (23)

1. Carini D. J., Duncia J. V., Aldrich P. E., Chiu A. T., Johnson A. L., Pierce M. E., Price W. A., Santella J. B., III, Wells G. J., Wexler R. R., Wong P. C., Yoo S.-E., Timmermans P. B. M. W. M., J. Med. Chem., 34, 2525-2547 (1991).
2. Bradbury R. H., Allott C. P., Dennis M., Fisher E., Major J. S., Masek B. B., Oldham A. A., Pearce R. J., Rankine N., Revill J. M., Roberts D. A., Russell S. T., J. Med. Chem., 35, 4027-4038 (1992).
3. Mantlo N. B., Chakravarty P. K., Ondeyka D. L., Siegl P. K. S., Chang R. S., Lotti V. J., Faust K. A., Chen T.-B., Schorn T. W., Sweet C. S., Emmert S. E., Patchett A. A., Greenlee W. J., J, Med. Chem., 34, 2919-2922 (1991).
4. De B., Winn M., Zydowsky T. M., Kerkman D. J., DeBernardis J. F., Lee J., Buckner S., Warner R., Brune M., Hancock A., Opgenorth T., Marsh K., J. Med. Chem., 35, 3714-3717 (1992).
5. Wexler R. R., Greenlee W. J., Irvin J. D., Goldberg M. R., Prendergast K., Smith R. D., Timmermans P. B. M. W. M., J. Med. Chem., 39, 625-656 (1996).
6. Kiyama R., Hayashi K., Hara M., Fujimoto M., Kawabata T., Kawakami M., Nakajima S., Fujishita T., Chem. Pharm. Bull., 43, 960-965 (1995).
7. Novinson T., Robins R. K., Matthews T. R., J. Med. Chem., 20, 296-299 (1977).
8. Huang H.-C., Reitz D. B., Chamberlain T. S., Olins G. M., Corpus V. M., McMahon E. G., Palomo M. A., Koepke J. P., Smits G. J., McGraw D. E., Blaine E. H., Manning R. E., J. Med. Chem., 36, 2172-2181 (1993).
9. O'Brien D. E., Viejo M., Robins R. K., Simon L. N., U. S. Patent, 3907799, Sept. 23 (1975) [Chem. Abstr., 84, 4998p (1975)].
10. Details of this regioselective reaction and structure determination of these compounds were reported in Shiota T., Yamamori T., J. Org. Chem., 64, 453-457 (1999).
11. Kubo K., Kohara Y., Yoshimura Y., Inada Y., Shibouta Y., Furukawa Y., Kato T., Nishikawa K., Naka T., J. Med. Chem., 36, 2343-2349 (1993).
12. Examples for incorporation of various hydrogen bonding groups are as follows. Examples of five-membered ring systems: a) Chang L. L., Ashton W. T., Flanagan K., L., Strelitz R. A., MacCoss M., Greenlee W. J., Chang R. S. L., Lotti V. J., Faust K. A., Chen T.-B., Bunting P., Zingaro G. J., Kilvlighn S. D., Siegl P. K. S., J. Med. Chem., 36, 2558-2568 (1993);
13. b)Ashton W. T., Hutchins S. M., Greenlee W. J., Doss G. A., Chang R. S. L., Lotti V. J., Faust K. A., Chen T.-B., Zingaro G. J., Kivlighn S. D., Siegl P. K. S., ibid., 36, 3595-3605 (1993);
14. c) Reitz D. B., Garland D. J., Olins G. M., Markos C. S., Gresk C. J., Litschgi J. W., McKinnis B. R., Bioorg. Med. Chem. Lett., 4, 111-114 (1994);
15. d) Reitz D. B., Penick M. A., Norton M. B., Reinhard E. J., Olins G. M., Corpus V. M., Palomo M. A., McGraw D. E., McMahon E. G., ibid., 4, 105-110 (1994);
16. e) Reitz D. B., Penick M. A., Reinhard E. J., Cheng B. K., Olins G. M., Corpus V M., Palomo M. A., McGraw D. E., McMahon E. G., ibid., 4, 99-104 (1994). Examples of fused imidazole systems:
17. f) Kubo K., Kohara Y., Imamiya E., Sugiura Y., Inada Y., Furukawa Y., Nishikawa K., Naka T., J. Med. Chem., 36, 2182-2195 (1993);
18. g) Yanagisawa T., Ueyama N., Kawai T., Sonegawa M., Baba H., Mochizuki S., Kozakai K., Tomiyama T., Bioorg. Med. Chem. Lett., 3, 1559-1564 (1993); and reference 3).
19. Abraham M. H., Duce P. P., Prior D. V, Barratt D. G., Morris J. J., Taylor P. J., J. Chem. Soc., Perkin Trans 2, 1355-1375 (1989).
20. SYBYL molecular modeling software; Tripos Inc., 1699 South Hanley Rd, Suite 303 St. Louis, MO 63144.
21. Itazaki K., Shigeri Y., Fujimoto M., Eur J. Pharmacol., 245, 147-156 (1993).
22. Chiu A. T., Herblin W. F., McCall D. E., Aldrich P. E., Timmermans P. B. M. W. M., Biochem. Biophys. Res. Commun., 172, 1195-1202 (1990).
23. Matsuda S., Kurokawa K., Higuchi K., Imamura N., Hakata H., Ueda M., J. Pharmacol Methods, 17, 361-376 (1987).